These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 19427871

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.
    Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
    Gupta RC, Chhipa L, Mandhare AB, Zambad SP, Chauthaiwale V, Nadkarni SS, Dutt C.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5021-5. PubMed ID: 19643608
    [Abstract] [Full Text] [Related]

  • 26. Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
    Zhang X, Wang Z, Huang Y, Wang J.
    Diabetes Obes Metab; 2011 Apr 01; 13(4):337-47. PubMed ID: 21205126
    [Abstract] [Full Text] [Related]

  • 27. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
    Nonogaki K, Kaji T.
    Diabetes Metab; 2015 Nov 01; 41(5):425-8. PubMed ID: 26234524
    [Abstract] [Full Text] [Related]

  • 28. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
    Idris I, Donnelly R.
    Diabetes Obes Metab; 2007 Mar 01; 9(2):153-65. PubMed ID: 17300591
    [Abstract] [Full Text] [Related]

  • 29. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y.
    Vasc Health Risk Manag; 2015 Mar 01; 11():229-43. PubMed ID: 25914541
    [Abstract] [Full Text] [Related]

  • 30. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z.
    Curr Opin Drug Discov Devel; 2008 Jul 01; 11(4):512-32. PubMed ID: 18600568
    [Abstract] [Full Text] [Related]

  • 31. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J, Peng L, Zhang G, Lan X, Li C, Chen F, Zhou Y, Lin Z, Chen L, Dai R, Xu H, Yang L, Zhang X, Hu W.
    Eur J Med Chem; 2011 Jan 01; 46(1):71-6. PubMed ID: 21106276
    [Abstract] [Full Text] [Related]

  • 32. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
    Nakamura Y, Inagaki M, Shimizu T, Fujita K, Inoue M, Gotoh H, Oguchi K, Goto Y.
    Nephron Clin Pract; 2013 Jan 01; 123(1-2):46-51. PubMed ID: 23774306
    [Abstract] [Full Text] [Related]

  • 33. Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Shibasaki M.
    Basic Clin Pharmacol Toxicol; 2008 Dec 01; 103(6):560-8. PubMed ID: 18793271
    [Abstract] [Full Text] [Related]

  • 34. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
    Roy S, Khanna V, Mittra S, Dhar A, Singh S, Mahajan DC, Priyadarsiny P, Davis JA, Sattigeri J, Saini KS, Bansal VS.
    Life Sci; 2007 Jun 13; 81(1):72-9. PubMed ID: 17532347
    [Abstract] [Full Text] [Related]

  • 35. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB.
    Diabetes; 2006 Jun 13; 55(6):1695-704. PubMed ID: 16731832
    [Abstract] [Full Text] [Related]

  • 36. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S.
    Eur J Pharmacol; 2012 Dec 05; 696(1-3):194-202. PubMed ID: 23022337
    [Abstract] [Full Text] [Related]

  • 37. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H, Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial.
    Diabetes Care; 2016 Jan 05; 39(1):139-48. PubMed ID: 26628419
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
    Tanaka-Amino K, Matsumoto K, Hatakeyama Y, Shima I, Takakura S, Muto S.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):444-9. PubMed ID: 18582861
    [Abstract] [Full Text] [Related]

  • 40. Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus.
    Gustavson SM, Dai H, Preston GM, Somayaji V, Hirshberg B, Calle RA.
    Diabetes Res Clin Pract; 2011 Feb 20; 91(2):e45-9. PubMed ID: 21130513
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.